Additional TRAVERSE data on testosterone therapy coming soon

[madman]

“Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub-studies,” says A. Michael Lincoff, MD.

Additional TRAVERSE data on testosterone therapy coming soon

“Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub studies,” says A. Michael Lincoff, MD.

www.urologytimes.com

In this video, A. Michael Lincoff, MD, discusses additional forthcoming data related to the New England Journal of Medicine study, “Cardiovascular Safety of Testosterone-Replacement Therapy.” Lincoff is vice chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine and an interventional cardiologist in the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic in Cleveland, Ohio.




Is there anything you would like to add?

Yes, I'd like to say, "Stay tuned." Because this was the largest trial ever of testosterone replacement therapy, although the primary point of the trial was cardiovascular safety, we embedded within the trial several efficacy and other sub-studies. Those are in the process of being submitted for publication and will be coming out. I'm not going to disseminate the results ahead of time, but I will say that there's a very thoughtful paper on prostate safety as well as effects on age-related anemia, sexual function, diabetes, progression from prediabetes to diabetes, and effects on bone fractures. Some of those were reported at The Endocrine Society annual meeting, but as I said, peer-reviewed publications are underway and we hope that they'll be coming out soon.

 

[madman]

TRT and Cardiovascular Disease

Testosterone replacement therapy and cardiovascular disease (2022) Jeremy M. Auerbach and Mohit Khera The use of testosterone therapy has a complex history of apprehension and questions regarding its safety. Despite an eventual consensus that testosterone therapy was safe and effective...

www.excelmale.com

Testosterone Therapy and erythrocytosis

Testosterone Therapy and Men’s Health – Demystifying the Hype with Science to Provide Cutting-Edge Treatment for Your Patients (2021) Summary 25:10-43:34 (Endocrine Society 2018 Guidelines) https://t4leducation.com/video/other-risks-with-testosterone-therapy-and-how-to-manage-them/

www.excelmale.com

Testosterone and Cardiovascular Disease (Traverse Trial)

www.excelmale.com

 

[Nelson Vergel]

I will post a video I am making today on my thoughts about heart palpitations and AFIB

 

[madman]

Testosterone Therapy and the Risk of Cardiovascular Disease

Abstract The debate over the cardiovascular (CV) implications of testosterone therapy (TT) have resulted in diverging safety recommendations and clinical guidelines worldwide. This narrative review synthesizes and critically evaluates long-term studies examining the effects of TT within the...

www.excelmale.com

4. Conclusion

The therapeutic approach for TT for symptomatic hypogonadism and low testosterone levels associated with aging, obesity, and systemic illness presents challenges. These conditions are intricately linked with CVD outcomes and may confound the relationship between low testosterone and CVD. Although observational studies suggest an association between low testosterone and increased risk of CVD, results from testosterone supplementation are inconsistent. RCTs indicate that short-term TT at standard replacement is not associated with increased CVD risk. Nevertheless, the cardiovascular sub-study of T Trials observed increases in NCP and CAC, signaling the need for further investigation into potential long-term implications of TT.

The TRAVERSE trial, a landmark study unique in its capacity to evaluate CVD events, contributes valuable insights into the short-term safety of TT at lower physiological levels. However, the long-term effects and implications of mid to high physiological testosterone levels are not yet fully understood. The trials’ limitations — achievement of only low-normal testosterone levels, high discontinuation rates, brief follow-up period, and high loss to follow-up rate — suggest that the findings should be interpreted with caution. It is important to avoid generalizing the safety of TT based on these results alone and to approach the extrapolation of TRAVERSE’s conclusions to higher dosages or longer-term therapy with caution.

The decision to initiate TT requires a nuanced approach, which must account for current gaps in evidence regarding CV safety. A personalized assessment and management of CVD risk factors is essential for older men with known CVD. The CV effects of exogenous testosterone, when given to maintain physiological levels, remain to be fully explored. In this regard, an important question remains the identification of male patients with symptomatic hypogonadism who may benefit from TT. This topic continues to be the subject of ongoing debate. Hopefully, future trials will provide clarity on whether TT confers beneficial, neutral, or adverse cardiovascular effects in middle-aged and older men. Until definitive evidence surfaces, clinical practice should exercise caution and prioritize individualized care with informed discussions regarding the potential CV implications of TT.